Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Clinical trials in non-PCOS populations showed tirzepatide users lost up to 22% of body weight at the highest dose, with significant improvements in fasting glucose and HbA1c levels
As your body adjusts to the absence of the medication, symptoms like hunger, weight gain, and high blood sugar (hyperglycemia) may return
Highlights GLP-1RAs improve PsO severity and metabolic parameters other than weight loss in PsO
However, current national supply constraints affecting semaglutide products may limit availability, and access may also depend on local service capacity for specialist weight management
This is not necessarily dangerous, but requires understanding that blood sugar effects may be unpredictable